Shandong Weigao Group Medical Polymer Co (1066) AI Stock Analysis

• Market Cap: $25.87B
• Dividend Yield: 3.6%
• Average Volume (3M): 9.91M
• Price to Earnings (P/E): 11.6
• Beta (1Y): 1.01
• Revenue Growth: -3.09%
• EPS Growth: 0.67%
• Country: HK
• Employees: 12,719
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.49
• Shares Outstanding: 4,522,332,000
• 10 Day Avg. Volume: 12,122,637
• 30 Day Avg. Volume: 9,908,565
• PEG Ratio: 41.45
• Price to Book (P/B): 8.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 188.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.20
• Price Target Upside: -11.99% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 74 Outperform
• Price Target: ―

Shandong Weigao Group Medical Polymer Co has a solid financial foundation with strong profitability and stable financial position, though it faces challenges in revenue growth and cash flow management. The stock's technical indicators suggest positive momentum, and its valuation is attractive, offering a reasonable P/E ratio and a solid dividend yield. These factors contribute to a moderately strong overall stock score.

Shandong Weigao Group Medical Polymer Co Business Overview & Revenue Model

Company Description

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound sutures, wound healing dressings, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. It also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, the company engages in the production and sale of orthopedic devices; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemodialysis equipment; and type I, type II, and type III medical devices. Further, it is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; provision of asset management, enterprise consulting, enterprise management advisory services, as well as logistics and storage services, as well as export its products. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.

How the Company Makes Money

Shandong Weigao Group Medical Polymer Co. makes money through the manufacture and sale of a diverse portfolio of medical products. Its key revenue streams include single-use medical devices such as syringes, infusion sets, and blood bags. Additionally, the company generates income from its orthopedic materials and blood purification equipment segments. The company benefits from strategic partnerships and collaborations with healthcare institutions, which help to expand its market reach and product offerings. Revenue is also driven by its strong distribution network and its ability to innovate and meet the growing demand for medical products both domestically and internationally.

Shandong Weigao Group Medical Polymer Co Financial Statement Overview

Summary

Shandong Weigao Group Medical Polymer Co demonstrates strong profitability and a stable financial position, with healthy margins and conservative leverage. However, the slight decline in revenue and the lack of detailed cash flow data for the latest year suggest areas for improvement, particularly in cash flow management and revenue growth.

Income Statement

The company shows strong profitability with a consistent gross profit margin around 50% and a stable net profit margin in the range of 15-20%. However, there has been a slight decline in revenue growth, with a negative growth rate of approximately -1.1% from the previous year. EBIT and EBITDA margins remain healthy, indicating efficient cost management.

Balance Sheet

The balance sheet reflects a stable financial position. The debt-to-equity ratio is low, suggesting prudent leverage, while the equity ratio indicates a strong equity base with around 68% of total assets financed by equity. Return on Equity (ROE) has been relatively stable, reflecting decent returns to shareholders.

Cash Flow

The company has shown positive free cash flow, though the free cash flow growth rate is unavailable for the latest year. The operating cash flow to net income ratio is not calculable due to missing operating cash flow data for the latest year, indicating potential cash flow management issues that need addressing.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
13.09B	13.23B	13.62B	13.15B	11.35B
	Gross Profit
6.58B	6.64B	7.11B	7.27B	6.46B
	EBIT
2.39B	2.18B	3.56B	3.32B	2.61B
	EBITDA
3.14B	3.55B	4.38B	3.75B	3.30B
	Net Income Common Stockholders
2.07B	2.00B	2.76B	2.28B	2.09B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
8.32B	7.33B	7.36B	7.06B	5.98B
	Total Assets
34.76B	33.67B	33.20B	30.37B	27.34B
	Total Debt
4.19B	4.17B	4.49B	4.14B	4.32B
	Net Debt
-3.59B	-2.82B	-2.37B	-2.49B	-1.19B
	Total Liabilities
9.42B	9.68B	9.75B	9.46B	8.95B
	Stockholders Equity
23.75B	22.45B	21.67B	19.27B	17.55B
Cash Flow		Free Cash Flow
2.14B	2.11B	1.10B	1.92B	1.70B
	Operating Cash Flow
2.79B	2.80B	2.21B	3.04B	2.70B
	Investing Cash Flow
-1.10B	-1.39B	-2.57B	-1.48B	423.22M
	Financing Cash Flow
-1.60B	-2.16B	-1.02B	-538.08M	-1.79B

Shandong Weigao Group Medical Polymer Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1066, the sentiment is Positive. The current price of 5.91 is above the 20-day moving average (MA) of 5.67, above the 50-day MA of 5.62, and above the 200-day MA of 4.87, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 60.93 is Neutral, neither overbought nor oversold. The STOCH value of 85.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1066.

Shandong Weigao Group Medical Polymer Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1066	74 Outperform	$25.87B	11.59	8.95%	3.60%	-3.09%	0.67%
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
50J		€968.83M	12.44	18.36%	3.92%	―	―
PWE		€177.74M	10.56	3.72%	8.47%	―	―
1MD		€434.51M	8.81	15.04%	4.47%	―	―
2276	68 Neutral	HK$16.05B	30.03	28.81%	1.05%	14.99%	31.70%
1501	66 Neutral	HK$4.52B	20.32	11.24%	1.17%	11.23%	20.39%

Shandong Weigao Group Medical Polymer Co Corporate Events

Shandong Weigao Group Announces Leadership Change

Shandong Weigao Group Medical Polymer Company Limited announced a change in its board leadership effective 28 May 2025. Mr. Tang Zhengpeng has resigned as Vice-Chairman but will continue his role as a non-executive Director and committee member. Ms. Yan Xia, previously a non-executive Director, will succeed him as Vice-Chairman. This leadership transition is part of the company’s strategic reassignment of duties and responsibilities, potentially impacting its governance and stakeholder relations.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Group Announces Board Composition

Shandong Weigao Group Medical Polymer Company Limited has announced the composition of its board of directors and their respective roles. This announcement provides clarity on the governance structure of the company, potentially impacting its strategic direction and operational oversight, which is crucial for stakeholders and investors.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Announces Final Dividend for 2024

Shandong Weigao Group Medical Polymer Co. has announced a final cash dividend of RMB 0.1235 per share for the financial year ending December 31, 2024, with shareholder approval scheduled for May 27, 2025. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.0888, with a payment date set for July 11, 2025. The announcement also details the withholding tax rates applicable to non-resident shareholders, with a 10% rate for enterprises and individuals outside China and a 20% rate for domestic individual investors using the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Group Announces Successful AGM and Dividend Payment

Shandong Weigao Group Medical Polymer Company Limited held its Annual General Meeting on 27 May 2025, where all proposed resolutions were successfully passed by poll. Key resolutions included the approval of the audited financial statements for 2024, the declaration of a final dividend, and the reappointment of Deloitte Touche Tohmatsu as the company’s auditor. The successful passing of these resolutions indicates strong shareholder support and positions the company for continued stability and growth.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Group Makes Regulatory Announcement

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. The announcement, which was also published on the Shanghai Stock Exchange’s website, highlights the company’s adherence to regulatory standards, potentially impacting its market positioning and stakeholder confidence positively.

Shandong Weigao Announces AGM with Key Resolutions

Shandong Weigao Group Medical Polymer Company Limited has announced its upcoming annual general meeting (AGM) scheduled for May 27, 2025. The AGM will address various resolutions, including the approval of the company’s audited financial statements for 2024, the declaration of a final dividend, re-appointment of auditors, and re-election of directors and supervisors. Additionally, a special resolution will consider granting the board a general mandate to issue and deal with shares. These resolutions are crucial for the company’s governance and strategic planning, potentially impacting its market positioning and shareholder value.

Shandong Weigao Group Announces Regulatory Compliance Update

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. This announcement, published on the Shanghai Stock Exchange website, signifies the company’s adherence to regulatory standards and may impact its market positioning by enhancing transparency and investor confidence.

Shandong Weigao Group Announces Overseas Regulatory Update

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. This announcement, published on the Shanghai Stock Exchange website, is part of the company’s ongoing regulatory obligations, reflecting its commitment to transparency and adherence to market regulations.

Shandong Weigao Group Makes Overseas Regulatory Announcement

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. The announcement was also published on the Shanghai Stock Exchange’s website, indicating the company’s adherence to regulatory standards and its commitment to transparency in its operations.

Shandong Weigao Group Announces Final Dividend for 2024

Shandong Weigao Group Medical Polymer Co has announced a final cash dividend of RMB 0.1235 per share for the financial year ending December 31, 2024. This announcement reflects the company’s financial health and commitment to returning value to its shareholders, potentially impacting its market positioning positively.

Shandong Weigao Group Reports Increased Profit Amid Revenue Dip

Shandong Weigao Group Medical Polymer Company Limited reported a slight decrease in revenue for the year ended December 31, 2024, with a total of approximately RMB13.09 billion, down 1.1% from the previous year. However, the company achieved a 3.2% increase in net profit attributable to its owners, reaching approximately RMB2.07 billion. The directors have recommended a final dividend of RMB0.1235 per share, pending shareholder approval. This financial performance highlights the company’s resilience and potential for growth despite a challenging market environment.

Shandong Weigao Group Schedules Board Meeting for Annual Results and Dividend Decision

Shandong Weigao Group Medical Polymer Co. announced that its board of directors will meet on March 26, 2025, to review and approve the audited annual results for the year ending December 31, 2024. The meeting will also consider the potential declaration of a final dividend, which could impact shareholder returns and reflect the company’s financial health.